Src inhibitors: drugs for the treatment of osteoporosis, cancer or both?
Src was one of the first proto-oncogenes to be identified and is a prototype of non-receptor type tyrosine kinases. The role of Src in bone metabolism first became apparent in Src-deficient mice and has been confirmed using low-molecular-weight Src inhibitors in animal models of osteoporosis. At the cellular level, it is well established that Src plays an important role in proliferation, and adhesion and motility. In addition, recent data indicate an involvement of Src in cell survival and intracellular trafficking in various specialized cell types. These new findings suggest that Src inhibitors might have therapeutic value in the suppression of tumor growth, tumor angiogenesis and bone resorption.
Susva
M
M
Arthritis and Bone Metabolism Therapeutic Area, Novartis Pharma Research, WKL-125. 9.12, CH-4002, Basel, Switzerland. arma.novartis.com
Missbach
M
M
Green
J
J
D000818:Animals; D001862:Bone Resorption / Q000188:drug therapy; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy; D010024:Osteoporosis / Q000188:drug therapy; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000037:antagonists & inhibitors*; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
D016392:Proto-Oncogene Proteins pp60(c-src); D019061:src-Family Kinases